# Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration：A Real World Exploratory Study

> **NCT03594682** · NA · UNKNOWN · sponsor: **Beijing Chest Hospital** · enrollment: 31 (estimated)

## Conditions studied

- NSCLC Stage IV
- NSCLC Stage IIIB

## Interventions

- **OTHER:** Intervention/treatment

## Key facts

- **NCT ID:** NCT03594682
- **Lead sponsor:** Beijing Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08
- **Primary completion:** 2019-07
- **Final completion:** 2020-07
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2018-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03594682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03594682, "Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration：A Real World Exploratory Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03594682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*